Emerging therapeutic options in age-related macular degeneration

Ophthalmic Research

Volumn 53, Issue 4, 2015, Pages 194-199

  Querques, Giuseppe ^a,b   Capuano, Vittorio ^a   Frascio, Pietro ^a,c   Bandello, Francesco ^b   Souied, Eric H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Abicipar pegol; Age related macular degeneration; Anti PDGF drugs; Anti VEGF drugs; Encapsulated cell technology; Fovista; Pazopanib; POT 4; Steroids; Zimura

Indexed keywords

AVACINCAPTAD PEGOL; COMPLEMENT INHIBITOR; PARVOVIRUS VECTOR; PEGPLERANIB; RANIBIZUMAB; STEROID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; CELL ENCAPSULATION; DRUG DELIVERY DEVICE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; HUMANS; MACULAR DEGENERATION; PLATELET-DERIVED GROWTH FACTOR; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84927947970     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000379754     Document Type: Review

References (16)

1. Nachod GR: ACTH and cortisone in ocular disease. J Am Med Womens Assoc1951; 6: 453-455.
2. Sarao V, Veritti D, Boscia F, Lanzetta P: Intravitreal steroids for the treatment of retinal diseases. Sci World J 2014; 2014: 989501.
3. Augustin AJ, Puls S, Oermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2009; 29: 573-578.
4. Loewenstein A, Kuppermann BD, Weinberger D, et al: Safety and efficacy of Ozurdex (dexamethasone intravitreal implant) as adjunctive therapy to Lucentis in patients with choroidal neovascularization secondary to age-related macular degeneration. Association for Research in Vision and Ophthalmology, Fort Lauderdale, May 2010.
5. Querques G, Rosenfeld PJ, Cavallero E, et al: Treatment of dry age-related macular degeneration. Ophthalmic Res 2014; 52: 107-115.
6. Bradley DT, Zipfel PF, Hughes AE: Complement in age-related macular degeneration: a focus on function. Eye 2011; 25: 683-693.
7. Kaushal S, Grossi F, Francois C, et al: Complement C3 inhibitor POT-4: clinical safety of intravitreal administration. Association for Research in Vision and Ophthalmology, Fort Lauderdale, May 2009.
8. Rofagha S, Bhisitkul RB, Boyer DS, et al: Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVENUP). Ophthalmology 2013; 120: 2292-2299.
9. Silva R, Axer-Siegel R, Eldem B, et al: The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013; 120: 130-139.
10. Grunwald JE, Daniel E, Huang J, et al: Risk of geographic atrophy in the comparison of agerelated macular degeneration treatments trials. Ophthalmology 2014; 121: 150-161.
11. Weber M, Sennlaub F, Souied EH, et al: Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data (in French). J Fr Ophtalmol 2014; 37: 566-579.
12. Wang Q, Li T, Wu Z, Wu Q, Ke X, Luo D, Wang H: Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One 2013; 8:e70544.
13. Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X; AURORA Study Group: Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 2014; 121: 1740.
14. Danis R, McLaughlin MM, Tolentino M, Staurenghi G, Ye L, Xu CF, Kim RY, Johnson MW; Pazopanib Eye Drops Study Group: Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. Br J Ophthalmol 2014; 98: 172-178.
15. Souied EH, Devin F, Mauget-Faysse M, Kolá P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S; MP0112 Study Group: Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 2014; 158: 724-732.
16. Mollnes TE, Song WC, Lambris JD: Complement in inflammatory tissue damage and disease. Trends Immunol 2002; 23: 61-64.